Economic Times | Roche, Prothena to develop new antibodies for Parkinson's disease treatment Pharmaceutical Business Review Roche and Prothena have agreed to jointly develop and commercialize new antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease (PD). Currently, PRX002 is in preclinical ... Roche and Prothena to Devlop Antibodies for Parkinson's Disease Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co ... Roche, Prothena in $600M Parkinson's... |
